Market Place
Sourcing Support
Positive results advance peanut tablet to phase II development
18 Dec 2024 //
GLOBENEWSWIRE
Acarizax approved in Europe for treatment of young children
12 Dec 2024 //
GLOBENEWSWIRE
Nine-month interim report (Q3) 2024 (unaudited)
14 Nov 2024 //
GLOBENEWSWIRE
ALK licenses rights to neffy for emergency treatment of Anaphylaxis
09 Nov 2024 //
GLOBENEWSWIRE
ALK Q3 2024 Results Presentation on Nov 14, 2024
07 Nov 2024 //
GLOBENEWSWIRE
Annual report 2022: ALK delivers sales growth of 13% with profits up 33% in 2022
03 Feb 2023 //
GLOBENEWSWIRE
Regulatory filing for house dust mite allergy tablet accepted for review
03 Feb 2023 //
GLOBENEWSWIRE
ALK – Financial calendar for the 2023 financial year
19 Dec 2022 //
GLOBENEWSWIRE
ALK spotlights the impact of respiratory allergies on children at EAACI Congress
03 Jul 2022 //
GLOBENEWSWIRE
ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
27 Jun 2022 //
GLOBENEWSWIRE
Azenta to Participate in the UBS Global Healthcare Conference
19 May 2022 //
PRNEWSWIRE
Clinical trial waiver in China opens door to 2022 registration filing
03 Mar 2022 //
GLOBENEWSWIRE
Merck shocks ALK by returning rights to allergy immunotherapies
28 Jul 2016 //
FIERCE BIOTECH
US FDA finds cGMP deviations at ALK-Abello facility in Denmark
26 Jul 2016 //
IN PHARMATECHNOLOGIST
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.